Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International (NYSE: VRX) today announced that Oxsoralen-Ultra®, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

Since last year, Valeant has experienced a shortage of Oxsoralen products due to an unanticipated change in the supplier of the product's active ingredient.

"Valeant understands the importance of Oxsoralen-Ultra to patients suffering from psoriasis, and we have been working diligently in partnership with the FDA to address the drug shortage," said Rajiv De Silva, chief operating officer of specialty pharmaceuticals. "We are pleased to be able to begin re-supplying Oxsoralen-Ultra to physicians and their patients on a limited basis and apologize for any issues this shortage has caused.  Valeant is committed to promptly getting this product back on pharmacy shelves."

Patients can obtain Oxsoralen-Ultra (Methoxsalen Capsules, USP, 10mg) with a prescription through their local pharmacies who will work with their wholesalers to arrange for shipment.